|
Valoración de DCF de Melexis NV (Mele.BR)
BE | Technology | Semiconductors | EURONEXT
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Melexis NV (MELE.BR) Bundle
¡Agilice su análisis y aumente la precisión con nuestra calculadora DCF (MeleBR)! Utilizando datos reales de Melexis NV y supuestos personalizables, esta herramienta le permite pronosticar, analizar y evaluar (Melebr) como un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 507.5 | 643.8 | 836.2 | 964.3 | 932.8 | 956.1 | 980.1 | 1,004.6 | 1,029.7 | 1,055.4 |
| Revenue Growth, % | 0 | 26.85 | 29.88 | 15.32 | -3.27 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
| EBITDA | 122.9 | 199.3 | 283.6 | 304.6 | 265.5 | 285.2 | 292.3 | 299.6 | 307.1 | 314.8 |
| EBITDA, % | 24.21 | 30.95 | 33.92 | 31.59 | 28.47 | 29.83 | 29.83 | 29.83 | 29.83 | 29.83 |
| Depreciation | 46.0 | 44.1 | 44.5 | 43.3 | 45.6 | 58.6 | 60.0 | 61.5 | 63.1 | 64.6 |
| Depreciation, % | 9.06 | 6.86 | 5.33 | 4.49 | 4.89 | 6.12 | 6.12 | 6.12 | 6.12 | 6.12 |
| EBIT | 76.9 | 155.1 | 239.1 | 261.3 | 219.9 | 226.6 | 232.3 | 238.1 | 244.1 | 250.2 |
| EBIT, % | 15.15 | 24.1 | 28.59 | 27.1 | 23.57 | 23.7 | 23.7 | 23.7 | 23.7 | 23.7 |
| Total Cash | 58.9 | 35.0 | 97.6 | 39.3 | 32.7 | 69.4 | 71.1 | 72.9 | 74.7 | 76.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 77.6 | 99.1 | 124.8 | 151.5 | .0 | 117.3 | 120.2 | 123.2 | 126.3 | 129.5 |
| Account Receivables, % | 15.29 | 15.39 | 14.93 | 15.71 | 0 | 12.27 | 12.27 | 12.27 | 12.27 | 12.27 |
| Inventories | 123.5 | 144.5 | 179.6 | 254.3 | 262.8 | 234.8 | 240.7 | 246.7 | 252.9 | 259.2 |
| Inventories, % | 24.33 | 22.44 | 21.49 | 26.38 | 28.17 | 24.56 | 24.56 | 24.56 | 24.56 | 24.56 |
| Accounts Payable | 18.3 | 22.7 | 28.7 | 79.7 | 63.2 | 49.0 | 50.2 | 51.4 | 52.7 | 54.1 |
| Accounts Payable, % | 3.61 | 3.52 | 3.44 | 8.26 | 6.78 | 5.12 | 5.12 | 5.12 | 5.12 | 5.12 |
| Capital Expenditure | -24.8 | -39.1 | -39.9 | -94.2 | -53.1 | -59.7 | -61.2 | -62.7 | -64.3 | -65.9 |
| Capital Expenditure, % | -4.89 | -6.07 | -4.77 | -9.77 | -5.69 | -6.24 | -6.24 | -6.24 | -6.24 | -6.24 |
| Tax Rate, % | 16.5 | 16.5 | 16.5 | 16.5 | 16.5 | 16.5 | 16.5 | 16.5 | 16.5 | 16.5 |
| EBITAT | 70.2 | 131.8 | 197.7 | 216.2 | 183.6 | 192.7 | 197.5 | 202.5 | 207.6 | 212.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -91.4 | 98.7 | 147.6 | 114.8 | 302.7 | 88.1 | 188.8 | 193.6 | 198.4 | 203.4 |
| WACC, % | 10.25 | 10.23 | 10.22 | 10.22 | 10.22 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 639.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 207 | |||||||||
| Terminal Value | 2,521 | |||||||||
| Present Terminal Value | 1,549 | |||||||||
| Enterprise Value | 2,189 | |||||||||
| Net Debt | 189 | |||||||||
| Equity Value | 1,999 | |||||||||
| Diluted Shares Outstanding, MM | 40 | |||||||||
| Equity Value Per Share | 49.44 |
Benefits You Will Receive
- Pre-Filled Financial Model: Leverage Melexis NV's (MELEBR) actual data for an accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth rates, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Instant updates allow you to view results immediately as you adjust inputs.
- Professional-Grade Template: An expertly designed Excel file oriented for investor presentations.
- Customizable and Reusable: Adapted for versatility, enabling ongoing use for in-depth forecasting.
Key Features
- Pre-Loaded Data: Melexis NV's historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Customize WACC, tax rates, revenue growth, and EBITDA margins.
- Instant Results: View Melexis NV's intrinsic value recalculating in real time.
- Clear Visual Outputs: Dashboard charts showcase valuation results and key metrics.
- Built for Accuracy: A professional-grade tool for analysts, investors, and finance experts.
How It Works
- Download the Template: Gain immediate access to the Excel-based MELEBR DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically calculates the intrinsic value of Melexis NV.
- Test Scenarios: Experiment with various assumptions to analyze potential valuation impacts.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis decisions.
Why Choose This Calculator for Melexis NV (MELEBR)?
- Accurate Data: Use genuine Melexis financials for trustworthy valuation outcomes.
- Customizable: Modify essential parameters like growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Pre-configured calculations allow you to bypass starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants working with Melexis NV (MELEBR).
- User-Friendly: Easy-to-navigate layout and detailed instructions make it accessible for all users.
Who Can Benefit from This Product?
- Investors: Evaluate Melexis NV’s (MELEBR) valuation prior to making stock trades.
- CFOs and Financial Analysts: Enhance valuation methodologies and validate financial forecasts.
- Startup Founders: Gain insights into how leading public companies like Melexis NV (MELEBR) are appraised.
- Consultants: Provide expert valuation analyses and reports to your clients.
- Students and Educators: Utilize real-world data for practicing and teaching valuation principles.
Contents of the Template
- Pre-Filled DCF Model: Melexis NV’s financial data preloaded for immediate utilization.
- WACC Calculator: Comprehensive calculations for Weighted Average Cost of Capital.
- Financial Ratios: Assess Melexis NV’s profitability, leverage, and operational efficiency.
- Editable Inputs: Adjust assumptions such as growth rates, profit margins, and CAPEX to suit your analysis.
- Financial Statements: Annual and quarterly reports to facilitate thorough evaluation.
- Interactive Dashboard: Effortlessly visualize essential valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.